FDA recall D-0330-2019

Mylan Laboratories Limited, (Nashik FDF) · Class II · drug

Product

Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg, (a) 90-count bottle (NDC 0378-6323-77), (b) 500-count bottles (NDC 0378-6323-05), Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.

Reason for recall

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Distribution

Product was distributed throughout the United States to several major distributors, including Puerto Rico.

Key facts

Status
Ongoing
Initiation date
2018-12-04
Report date
2018-12-19
Voluntary/Mandated
Voluntary: Firm initiated
Location
Sinnar, Nashik District, N/A, India

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0330-2019